RxDoctor Payments DataLook up a doctor →

Mavis Matsumoto, MD

Internal Medicine · Henderson, NVNPI 1942213558

Payments from drug & device makers

$1,814,958in general payments, 2019–2025

Across 446 payments — averaging $4069.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bavarian Nordic A/s$1.1M
  • Sanofi Pasteur Inc.$407K
  • Vertex$91K
  • Braintree Laboratories, Inc.$66K
  • AstraZeneca$36K
  • Madrigal Pharmaceuticals$28K
  • plus $48K from 46 others

What the payments were for

  • Consulting fees$1,20011%
  • Food & beverage$9,45988%
  • Education$741%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,814,958 in reported general payments places this provider in the 95th percentile of 1,071 internal medicine providers in Nevada.

See all internal medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$128,470
Medicare patients
227
Services billed
1,554

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban47$51,818
MounjaroTirzepatide50$49,425
EliquisApixaban30$48,673
TrulicityDulaglutide31$38,256
OzempicSemaglutide29$37,134
ProliaDenosumab21$36,878
RybelsusSemaglutide36$36,486
JardianceEmpagliflozin29$35,159
Repatha SureclickEvolocumab36$34,221
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$26,520
EntrestoSacubitril/Valsartan22$25,065
Dexlansoprazole DrDexlansoprazole31$13,648
Breo ElliptaFluticasone/Vilanterol19$11,554
VascepaIcosapent Ethyl14$4,917
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$4,836

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$364$87,68181 claims
Novo NordiskOzempic, Rybelsus$189$73,62065 claims
Johnson & JohnsonXarelto$315$51,81847 claims
PfizerEliquis$236$48,67330 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$941$42,91049 claims
AmgenProlia$846$36,87821 claims
Boehringer IngelheimJardiance$626$35,15929 claims
NovartisEntresto$126$25,06522 claims
AbbVieSynthroid$918$3,17747 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,071 internal medicine providers in Nevada.

Other internal medicine in Henderson

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →